Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership of Aitrox from 28.23% to 72.63% in a deal valued at RMB 412.35 million (USD 61 million). The investment includes a direct capital injection of RMB 50 million (USD 7.4 million) and the acquisition of another company’s stake for RMB 362.35 million (USD 53.6 million). Post-transaction, Aitrox will be consolidated into Fosun’s financial statements.
About Aitrox
Founded in 2018, Aitrox specializes in medical imaging and pathology AI software and digital solutions. Its product pipeline covers imaging, pathology, and information systems. The firm uses AI to analyze medical images and diagnose diseases such as lung, coronary, thyroid, breast, and cervical conditions. Aitrox holds 1 Category III and 6 Category II medical device approvals, with over 40 AI diagnosis products used in more than 500 Chinese hospitals.-Fineline Info & Tech
